Business
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: M...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement\n\n\n\n TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has begun production on novel cannabis metered dose inhalers for the EU and the United Kingdom, made to global pharmaceutical standards and distributed by Blackpoint Limited (“Blackpoint”), MediPharm’s exclusive sales and distribution partner in those territories.\n \n\n This discreet and innovative product provides patients with a smoke-free option when seeking fast onset of effects without combustion or heating. The cannabis metered dose inhaler, manufactured by MediPharm Labs under Good Manufacturing Practices (“GMP”), delivers a precise dose of cannabis active pharmaceutical ingredients (API) with GMP-qualified components and excipients.\n \n\n MediPharm Labs has launched metered dose inhalers in the Canadian Adult Use & Wellness and Medical channels and expects to launch in Australia, the EU and the United Kingdom in Q3 of this year.\n \n\n\n Management Commentary:\n \n\n\n David Pidduck, CEO of MediPharm Labs, commented, \"We’re excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler to the EU and United Kingdom. This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products. Successfully launching in these markets reflects the strength of our global execution strategy and our ability to manage the complexities of international compliance, logistics, and market access.”\n \n\n David Martinez, CEO of Blackpoint, added, \"Working together with the highly capable team at MediPharm is exciting and we look forward to introducing our novel and much needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom.”\n \n\n\n Additional highlights:\n \n\n\n\n\n EU & United Kingdom Exclusive Supply and Distribution:\n \n MediPharm Labs is the ...